Joel Lexchin1. 1. School of Health Policy and Management, York University, and University Health Network and Faculty of Medicine, University of Toronto, Toronto, Ont. jlexchin@yorku.ca.
Abstract
BACKGROUND: Health Canada supplements its in-house expertise on pharmacotherapy and pharmaceutical policy through the use of scientific/expert advisory committees and scientific/expert advisory panels. This study was undertaken to examine the interests of the members of these Health Canada advisory bodies. METHODS: This was an observational study of the financial and intellectual interests of members of Health Canada's scientific/expert advisory committees and panels. The following information was extracted from Health Canada websites in December 2018: member's name, name of committee/panel, direct and indirect financial interests, and intellectual interests. Information extracted about the committees and panels included the number of meetings for which a record of proceedings was available and the topics discussed at the meetings. RESULTS: Of 81 unique committee and panel members, 12 declared a direct financial interest, 56 an indirect financial interest and 65 an intellectual interest. Five of 11 committees and panels had people who declared a direct financial interest. All 11 advisory bodies had members who declared indirect financial interests (n = 62) and intellectual interests (n = 81). Six of the 11 committees and panels had a majority of members who declared a direct or indirect financial interest. In the 10 advisory body meetings for which information was available, individual products were rarely discussed but recommendations from all but 1 of the meetings could potentially have affected sales. INTERPRETATION: Only a minority of members of Health Canada's advisory committees and panels declared direct financial interests but the majority of members of a majority of the advisory bodies declared indirect financial and intellectual interests. Because of the lack of individual voting records it was not possible to determine if financial or intellectual interests influenced voting patterns. Copyright 2019, Joule Inc. or its licensors.
BACKGROUND: Health Canada supplements its in-house expertise on pharmacotherapy and pharmaceutical policy through the use of scientific/expert advisory committees and scientific/expert advisory panels. This study was undertaken to examine the interests of the members of these Health Canada advisory bodies. METHODS: This was an observational study of the financial and intellectual interests of members of Health Canada's scientific/expert advisory committees and panels. The following information was extracted from Health Canada websites in December 2018: member's name, name of committee/panel, direct and indirect financial interests, and intellectual interests. Information extracted about the committees and panels included the number of meetings for which a record of proceedings was available and the topics discussed at the meetings. RESULTS: Of 81 unique committee and panel members, 12 declared a direct financial interest, 56 an indirect financial interest and 65 an intellectual interest. Five of 11 committees and panels had people who declared a direct financial interest. All 11 advisory bodies had members who declared indirect financial interests (n = 62) and intellectual interests (n = 81). Six of the 11 committees and panels had a majority of members who declared a direct or indirect financial interest. In the 10 advisory body meetings for which information was available, individual products were rarely discussed but recommendations from all but 1 of the meetings could potentially have affected sales. INTERPRETATION: Only a minority of members of Health Canada's advisory committees and panels declared direct financial interests but the majority of members of a majority of the advisory bodies declared indirect financial and intellectual interests. Because of the lack of individual voting records it was not possible to determine if financial or intellectual interests influenced voting patterns. Copyright 2019, Joule Inc. or its licensors.
Authors: Camilla Hansen Nejstgaard; Lisa Bero; Asbjørn Hróbjartsson; Anders W Jørgensen; Karsten Juhl Jørgensen; Mary Le; Andreas Lundh Journal: Cochrane Database Syst Rev Date: 2020-12-08